Cipepofol

Cipepofol

SCHEMBL17533281

CC(C)c1cccc(C(C)C2CC2)c1O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Cipepofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 known ✓ P14867 7/20 0.65
GABRB1 known ✓ P18505 5/20 0.65
GABRB2 known ✓ P47870 3/20 0.65
GABRG2 known ✓ P18507 2/20 0.65
GABRB3 known ✓ P28472 2/20 0.65
GABRA5 known ✓ P31644 1/20 0.65
GABRA3 known ✓ P34903 1/20 0.65
GABRA2 known ✓ P47869 1/20 0.65
GABRA4 known ✓ P48169 1/20 0.65
GABRA6 known ✓ Q16445 1/20 0.65
CYP1A2 P05177 3/20 0.65
CA1 P00915 2/20 0.65
CA2 P00918 2/20 0.65
CYP3A4 P08684 2/20 0.65
LMNA P02545 2/20 0.65
HIF1A Q16665 2/20 0.65
FAAH O00519 1/20 0.65
HPGD P15428 1/20 0.65
TSHR P16473 1/20 0.65
PTGS1 P23219 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cipepofol SCHEMBL17515121 1.00 GABRA1 (0.65) GABRA1GABRB1GABRB2CYP1A2GABRG2
Cipepofol SCHEMBL30001127 1.00 GABRA1 (0.65) GABRA1GABRB1GABRB2CYP1A2GABRG2
Cipepofol SCHEMBL17537109 1.00 GABRA1 (0.65) GABRA1GABRB1GABRB2CYP1A2GABRG2
Cipepofol SCHEMBL17515120 1.00 GABRA1 (0.65) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17565217 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17565218 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17537206 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17537205 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17537117 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2
SCHEMBL17537082 0.94 GABRA1 (0.54) GABRA1GABRB1GABRB2CYP1A2GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113521038-A Anesthetic pharmaceutical composition and application thereof 海思科医药集团股份有限公司 2021-10-22 CN claimed
CN-113521038-B Anesthetic pharmaceutical composition and application thereof 西藏海思科制药有限公司 2025-08-01 CN disclosed
CN-118791364-A Cycloparaffin intermediate and preparation method of cycloparaffin 山东百诺医药股份有限公司 2024-10-18 CN disclosed
EP-3189834-B1 USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT HAISCO INNOVATIVE PHARMACEUTICAL PTE LTD (SG) 2024-01-17 EP disclosed
CN-117091929-A Method for rapidly extracting and detecting cycloparaffin from suspension or body fluid 中国科学院大连化学物理研究所 2023-11-21 CN disclosed
CN-116829523-A Phenol derivative, crystal form and preparation method thereof 天地恒一制药股份有限公司 2023-09-29 CN disclosed
US-20230118143-A1 PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-04-20 US disclosed
CN-113801004-A Phenyl bisphenol derivative, preparation method and medical application thereof 四川海思科制药有限公司 2021-12-17 CN disclosed
CN-109415285-B Phenyl bisphenol derivative, preparation method and medical application thereof 四川海思科制药有限公司 2021-12-14 CN disclosed
WO-2021239130-A1 PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREFOR 四川海思科制药有限公司 2021-12-02 WO disclosed
WO-2016034079-A1 USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT 四川海思科制药有限公司 2016-03-10 WO disclosed
WO-2016034079-A1 USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT 四川海思科制药有限公司 2016-03-10 WO disclosed
CN-105384607-A Isopropyl-phenol derivative and preparation method therefor SICHUAN HAISCO PHARMACEUTICAL CO LTD 2016-03-09 CN disclosed
CN-105384604-A Isopropyl-phenol derivative and preparation method therefor SICHUAN HAISCO PHARMACEUTICAL CO LTD 2016-03-09 CN disclosed
CN-105384619-A Isopropyl-phenol derivative and preparation method therefor SICHUAN HAISCO PHARMACEUTICAL CO LTD 2016-03-09 CN disclosed
US-20160060197-A1 PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2016-03-03 US disclosed
US-20160060197-A1 PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2016-03-03 US disclosed
US-20160060197-A1 PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2016-03-03 US disclosed
WO-2016026459-A1 ISOPROPYL PHENOL DERIVATIVE AND PREPARATION METHOD THEREOF 四川海思科制药有限公司 2016-02-25 WO disclosed
CN-104507899-A Phenol derivative, preparation method and medical application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2015-04-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060197-A1 PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF CYP2D6, CYP2B6, CYP2A6 GABRA1 2665/4885GABRB1 3276/4885GABRB2 3304/4885
US-20230118143-A1 PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREFOR GABRA1, GABRR1, GABARAPL1 GABRA1 1/4885GABRB1 5/4885GABRB2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.